Why the study?
Does certoparin reduce venous thromboembolism in ambulatory patients with metastatic breast cancer or stage III/IV lung cancer?
Does certoparin reduce venous thromboembolism in ambulatory patients with metastatic breast cancer or stage III/IV lung cancer?
Prophylactic certoparin did not significantly reduce VTE in the overall cohorts of metastatic breast or stage III/IV lung cancer, but may offer benefit in stage IV lung cancer.
Answers are grounded in this paper and cite their sources.
Certoparin does not support routine VTE prophylaxis in these cohorts; challenges broad LMWH use while leaving open targeted benefit in stage IV lung cancer.
In 2 double-blind studies, ambulatory patients with objectively proven, disseminated metastatic breast carcinoma (TOPIC-1) or stage III/IV non-small-cell lung carcinoma (TOPIC-2) were randomized to certoparin 3000 IU or placebo subcutaneously once daily, for 6 months. Primary efficacy outcome was objectively confirmed symptomatic or asymptomatic venous thromboembolism (VTE). Safety outcomes included bleeding (major and minor), and thrombocytopenia. TOPIC-1 was halted after an interim analysis. Venous thromboembolism occurrence was not different between treatment groups in TOPIC-1 (4% treated with certoparin, 7 of 174 vs 4% receiving placebo, 7 of 177, odds ratio [OR] 1.02; 95% confidence interval [CI] 0.30-3.48) and in TOPIC-2 (4.5%, 12 of 268) vs 8.3%, 22 of 264, respectively, OR 0.52; CI 0.23-1.12). Mortality was not different between groups. A post hoc analysis showed certoparin significantly reduced VTE in stage IV lung carcinoma (3.5% vs 10.2%; P = .032) without increased bleeding. In conclusion, thrombosis risk and prophylactic benefit was highest in stage IV lung carcinoma patients.
No takes yet. Share an insight, caveat, or question.
Haas et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: